“Continuing to boost top-line growth when patents are expiring on key drugs is very difficult to achieve . . . but it will not stop companies from trying, it is a dynamic that means the merits of such megadeals do not always receive adequate scrutiny.”
Media
Patent Panic Gives Green Light to Deals (Financial Times)
The recent announcement of pharma’s latest mega-merger has not been received well by many people, except perhaps Allergan Shareholders. The deal has been highlighted as another defensive mega-merger to protect against patent expiry.
In light of this the Financial Times asked John Rountree for his views on the deal:
“Continuing to boost top-line growth when patents are expiring on key drugs is very difficult to achieve . . . but it will not stop companies from trying, it is a dynamic that means the merits of such megadeals do not always receive adequate scrutiny.”
Pharma M&A is a topic we have discussed frequently and how greater value can be found partnering and strategic collaborations.
Related
Media
How Pharma Manages Organisational Complexity (MedNous)
DiscoverHow R&D Teams Create Value from On-Market Products (MedNous)
DiscoverHow European MidPharmas have Grown Profits (MedNous)
Discover